Literature DB >> 16906324

Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy.

Juan F Navarro1, Carmen Mora.   

Abstract

Diabetes and its complications have become a public health problem. Diabetic nephropathy is the main cause of renal failure. In spite of our higher knowledge on this complication, the intimate mechanisms leading to the development and progression of renal injury are not yet fully known. Activated innate immunity and inflammation are relevant factors in the pathogenesis of diabetes. Moreover, inflammation, and more specifically proinflammatory cytokines and other molecules with a relevant role within the inflammatory process, may be critical factors in the development of microvascular diabetic complications, including nephropathy. This new pathogenic perspective may lead to important new therapeutic considerations and new therapeutic goals for the treatment of diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16906324      PMCID: PMC5917399          DOI: 10.1100/tsw.2006.179

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  32 in total

1.  Histone demethylase UTX is a therapeutic target for diabetic kidney disease.

Authors:  Hong Chen; Yixue Huang; Xiuqin Zhu; Chong Liu; Yangmian Yuan; Hua Su; Chun Zhang; Chengyu Liu; Mingrui Xiong; Yannan Qu; Peng Yun; Ling Zheng; Kun Huang
Journal:  J Physiol       Date:  2018-12-25       Impact factor: 5.182

2.  Evidence for the link between defective autophagy and inflammation in peripheral blood mononuclear cells of type 2 diabetic patients.

Authors:  Samira Alizadeh; Hossein Mazloom; Asie Sadeghi; Solaleh Emamgholipour; Abolfazl Golestani; Farshid Noorbakhsh; Mohsen Khoshniatnikoo; Reza Meshkani
Journal:  J Physiol Biochem       Date:  2018-04-13       Impact factor: 4.158

3.  Angiotensin-(1-7) administration benefits cardiac, renal and progenitor cell function in db/db mice.

Authors:  A M Papinska; N M Mordwinkin; C J Meeks; S S Jadhav; K E Rodgers
Journal:  Br J Pharmacol       Date:  2015-07-30       Impact factor: 8.739

4.  Increased IL-12 and decreased IL-33 serum levels are associated with increased Th1 and suppressed Th2 cytokine profile in patients with diabetic nephropathy (CURES-134).

Authors:  Gowrishankar Anand; Rathinam Vasanthakumar; Vishwanathan Mohan; Subash Babu; Vivekanandhan Aravindhan
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

5.  Proinflammatory CD14+CD16+ monocytes are associated with microinflammation in patients with type 2 diabetes mellitus and diabetic nephropathy uremia.

Authors:  Mengxue Yang; Hua Gan; Qing Shen; Weixue Tang; Xiaogang Du; Danyan Chen
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

6.  Effects of 1,25-(OH)(2)D (3) on the expressions of vitamin D receptor, STAT5 and cytoskeletal rearrangement in human monocytes incubated with sera from type 2 diabetes patients and diabetic nephropathy patients with uremia.

Authors:  Mengxue Yang; Zhaonan Shen; Danyan Chen; Hua Gan; Qing Shen; Bo Yang; XiaoGang Du
Journal:  Inflamm Res       Date:  2012-02-10       Impact factor: 4.575

7.  Immunophenotypic profile of leukocytes in hyperandrogenemic female rat an animal model of polycystic ovary syndrome.

Authors:  Mohadetheh Moulana
Journal:  Life Sci       Date:  2019-01-29       Impact factor: 5.037

8.  The effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat.

Authors:  Carolyn M Ecelbarger; Arjun Rash; Rajesh K Sinha; Swasti Tiwari
Journal:  Mediators Inflamm       Date:  2010-05-17       Impact factor: 4.711

9.  Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis.

Authors:  Keizo Kanasaki; Gangadhar Taduri; Daisuke Koya
Journal:  Front Endocrinol (Lausanne)       Date:  2013-02-06       Impact factor: 5.555

10.  Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications.

Authors:  Emma Börgeson; Catherine Godson
Journal:  Front Immunol       Date:  2012-10-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.